OneSource Specialty Pharma Limited has announced that its partner Dr. Reddy’s Laboratories has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic.

OneSource is serving as the contract development and manufacturing organisation (CDMO) partner for the programme, providing scale-up and manufacturing support. The collaboration aims to ensure reliable, large-scale commercial supply from OneSource’s US FDA-approved flagship manufacturing facility in Bengaluru.

Neeraj Sharma, CEO & MD, OneSource Speciality Pharma Limited, speaking on the development, said: “We are pleased to announce that our partner Dr. Reddy’s has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic®. This approval further strengthens our collaboration, combining Dr. Reddy’s expertise in peptide development with OneSource’s CDMO capabilities.”